Literature DB >> 11032090

Biopharmaceutical characterisation of herbal medicinal products: are in vivo studies necessary?

H H Blume1, B S Schug.   

Abstract

Herbal medicinal products have to meet comparable standards concerning the assessment of efficacy, safety and (bio)pharmaceutical quality as chemically defined synthetic drugs. However, these requirements are not fulfilled for many herbal products so far, particularly regarding in vitro dissolution and in vivo bioavailability. The necessity of in vivo studies for a biopharmaceutical characterisation of the products depends on the solubility/permeability properties of the active drug ingredient as well as dissolution behaviour of the dosage form. Also, in the case of herbal medicinal products, a waiver of in vivo BA/BE studies is recommended as long as the active ingredient is highly soluble according to the Biopharmaceutics Classification System and dissolution of the dosage form takes place rapidly (>85%/20 min) in physiological buffer systems (pH 1-8).

Mesh:

Year:  2000        PMID: 11032090     DOI: 10.1007/BF03190057

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  12 in total

Review 1.  The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver?

Authors:  H H Blume; B S Schug
Journal:  Eur J Pharm Sci       Date:  1999-12       Impact factor: 4.384

2.  Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans.

Authors:  J Brockmöller; T Reum; S Bauer; R Kerb; W D Hübner; I Roots
Journal:  Pharmacopsychiatry       Date:  1997-09       Impact factor: 5.788

3.  A new technique for segmental jejunal perfusion in man.

Authors:  L Knutson; B Odlind; R Hällgren
Journal:  Am J Gastroenterol       Date:  1989-10       Impact factor: 10.864

4.  [The solubility and bioequivalence of silymarin preparations].

Authors:  H U Schulz; M Schürer; G Krumbiegel; W Wächter; R Weyhenmeyer; G Seidel
Journal:  Arzneimittelforschung       Date:  1995-01

5.  In vitro-in vivo relationships of several "immediate" release tablets containing a low permeability drug.

Authors:  J E Polli
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

6.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

7.  Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract.

Authors:  W E Müller; A Singer; M Wonnemann; U Hafner; M Rolli; C Schäfer
Journal:  Pharmacopsychiatry       Date:  1998-06       Impact factor: 5.788

8.  Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers.

Authors:  A Biber; H Fischer; A Römer; S S Chatterjee
Journal:  Pharmacopsychiatry       Date:  1998-06       Impact factor: 5.788

9.  Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers.

Authors:  B Staffeldt; R Kerb; J Brockmöller; M Ploch; I Roots
Journal:  J Geriatr Psychiatry Neurol       Date:  1994-10       Impact factor: 2.680

10.  EEG profile of three different extractions of Ginkgo biloba.

Authors:  H Künkel
Journal:  Neuropsychobiology       Date:  1993       Impact factor: 2.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.